Missing: Novai's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Novai's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Novai
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Novai is included in 4 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Clinical Trials Tech
Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Latest Novai News
Jul 6, 2022
UKHotViews Sponsored Post Primary Access & Research , a venture capital consultancy focused on healthcare, technology and industry disruption introduces Novai’s Series A fundraise to drive their innovative DARC Technology to address the biggest challenges in ophthalmology. Novai is a UK-based biotech company whose proprietary DARC (Detection of Apoptosing Retinal Cells) technology is used for the identification of dying and stressed cells in the retina using standard imaging equipment and Novai’s patented AI algorithm. DARC has already been approved as an exploratory biomarker in glaucoma and age-related macular degeneration clinical trials. By assessing drug efficacy in weeks rather than years DARC biomarker substantially reduces the time and costs of clinical trials. Francesca Cordeiro, CSO and interim CEO of Novai, is the inventor of DARC technology and an international expert in Ophthalmology, recognised for her pioneering work in retinal neurodegeneration, being the recipient of multiple awards. Novai offer a unique platform technology and are raising their Series A round to fund the Phase 2b trial and gain approval of DARC as a recognised clinical endpoint in glaucoma. This would automatically support its use as a diagnostic and lead to the advancement of Novai’s targeted drug delivery programme, as the same biologic is used in all applications. Both diagnostic and theranostic platforms build on the proven science of the biomarker and positive preliminary data and therefore have a much-reduced risk profile. You can find out more about Novai’s technology and other advancements in ophthalmic diagnostics in the accompanying research published by Primary Access & Research.
Novai Web Traffic
Novai Frequently Asked Questions (FAQ)
When was Novai founded?
Novai was founded in 2019.
Where is Novai's headquarters?
Novai's headquarters is located at 221 Pentonville Road, London.
What is Novai's latest funding round?
Novai's latest funding round is Seed VC.
How much did Novai raise?
Novai raised a total of $640K.
Who are the investors of Novai?
Investors of Novai include SFC Capital.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.